Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
neprilysin inhibitor
|
| gptkbp:affects |
improved exercise capacity
reduced mortality decreased hospitalization for heart failure increased diuresis reduced cardiac workload |
| gptkbp:approves |
gptkb:2015
gptkb:FDA |
| gptkbp:brand |
gptkb:Entresto
|
| gptkbp:can_be_used_with |
valsartan
|
| gptkbp:clinical_trial |
approximately 60%
Phase III heart failure with preserved ejection fraction heart failure with reduced ejection fraction |
| gptkbp:contraindication |
pregnancy
angioedema lactation |
| gptkbp:dosage_form |
gptkb:sacubitril/valsartan
gptkb:tablet |
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
sacubitril
|
| gptkbp:indication |
chronic heart failure
|
| gptkbp:ingredients |
C22 H30 N2 O5 S
|
| gptkbp:interacts_with |
gptkb:ACE_inhibitors
lithium diuretics potassium-sparing diuretics NSAI Ds |
| gptkbp:is_atype_of |
C09 B X04
|
| gptkbp:is_used_for |
heart failure
|
| gptkbp:lifespan |
approximately 12 hours
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:Novartis
|
| gptkbp:metabolism |
liver
|
| gptkbp:population |
adults
elderly patients with heart failure patients with preserved ejection fraction patients with reduced ejection fraction |
| gptkbp:provides_information_on |
ACC/ AHA guidelines
ESC guidelines |
| gptkbp:research_areas |
cardiology
clinical trials pharmacology |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
cough
renal impairment hypotension hyperkalemia |
| gptkbp:targets |
natriuretic peptides
|
| gptkbp:traded_on |
gptkb:Entresto
|
| gptkbp:bfsParent |
gptkb:Entresto
|
| gptkbp:bfsLayer |
4
|